Management of cardiovascular risk in patients with metabolic dysfunction-associated steatotic liver disease

Mellemkjær, Anders; Kjær, Mikkel Breinholt; Haldrup, David; Grønbæk, Henning; Thomsen, Karen Louise

doi:10.1016/j.ejim.2023.11.012

Cited by 24 publications

(10 citation statements)

References 87 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Knowledge regarding the association between MASLD (and its evolving condition, NASH) and dyslipidemia is well established in the literature; recently, some Greek researchers delved into the role of treatment with lipid-lowering drugs (specifically statins) in populations affected by both MASLD and NASH, concluding on the safety and usefulness of statin pharmacological treatment. Statins were found to reduce both the overall CV risk in these individuals [70] and the theoretical possibility of progression to more aggressive forms of liver disease, such as hepatocellular carcinoma (HCC) [71].…”

Section: Discussionmentioning

confidence: 99%

“…In recent years, MASLD has been the subject of various association studies, which have demonstrated its association with significantly different conditions, such as obesity, insulin resistance, and T2DM, as explained in the introductory part of the study, as well as with community-acquired pneumonia [70], colonic polyposis [71], and breast cancer [72]. Recently, MASLD has also been associated with an increased severity of acute pancreatitis [73] and acute cholangitis [7], both conditions that are certainly more homogeneous and conceptually more related to liver disease; in the latter case, in particular, MASLD has shown a significant association with acute biliary disease, especially in individuals presenting to the physician with symptomatic gallstones.…”

Section: Masld and Acute Biliary Diseasementioning

confidence: 99%

See 1 more Smart Citation

Dyslipidemia, Cholangitis and Fatty Liver Disease: The Close Underexplored Relationship: A Narrative Review

Greco,

Campigotto,

D’Amuri

et al. 2024

JCM

View full text Add to dashboard Cite

In assessing individual cardiovascular risk, dyslipidemia is known for emerging as a pivotal factor significantly contributing to major cardiovascular events. However, dyslipidemic patients frequently present with concurrent medical conditions, each with varying frequencies of occurrence; cholangitis, whether acute or chronic, and hepatic steatosis, along with associated conditions, are strongly associated with specific forms of dyslipidemia, and these associations are reasonably well elucidated. Conversely, evidence linking biliary disease to hepatic steatosis is comparatively scant. This narrative review aims to bridge this gap in knowledge concerning the interplay between dyslipidemia, cholangitis, and hepatic steatosis. By addressing this gap, clinicians can better identify patients at heightened risk of future major cardiovascular events, facilitating more targeted interventions and management strategies. The review delves into the intricate relationships between dyslipidemia and these hepatic and biliary clinical conditions, shedding light on potential mechanisms underlying their associations. Understanding these complex interactions is crucial for optimizing cardiovascular risk assessment as well and devising tailored treatment approaches for patients with dyslipidemia and associated hepatic disorders. Moreover, elucidating these connections empowers clinicians with the knowledge needed to navigate the multifaceted landscape of cardiovascular risk assessment and management effectively. By exploring the intricate relationships between dyslipidemia, cholangitis, and hepatic steatosis (without forgetting the possible clinical consequences of hepatic steatosis itself), this review not only contributes to the existing body of knowledge but also offers insights into potential avenues for further research and clinical practice. Thus, it serves as a valuable resource for healthcare professionals striving to enhance patient care and outcomes in the context of cardiovascular disease and associated hepatic conditions.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Masld and Acute Biliary Diseasementioning

confidence: 99%

Dyslipidemia, Cholangitis and Fatty Liver Disease: The Close Underexplored Relationship: A Narrative Review

Greco,

Campigotto,

D’Amuri

et al. 2024

JCM

View full text Add to dashboard Cite

show abstract

“…If an individual with MASLD consumes excess alcohol, the term is modified to MetALD (metabolic and alcohol-related/associated liver disease [4]. Importantly, these disorders are the most common causes of steatohepatitis and cirrhosis [5 ▪▪ ,6]. SLD can also be a consequence of viral infections or therapies that increase liver fat, such as antibiotic tetracycline or antiarrhythmic agent amiodarone.…”

Section: Introductionmentioning

confidence: 99%

Basic and translational evidence supporting the role of TM6SF2 in VLDL metabolism

Liu,

Ginsberg,

Reyes-Soffer

2024

Current Opinion in Lipidology

View full text Add to dashboard Cite

Purpose of review Transmembrane 6 superfamily member 2 (TM6SF2) gene was identified through exome-wide studies in 2014. A genetic variant from glutamic acid to lysine substitution at amino acid position 167 (NM_001001524.3:c.499G> A) (p.Gln167Lys/p.E167K, rs58542926) was discovered (p.E167K) to be highly associated with increased hepatic fat content and reduced levels of plasma triglycerides and LDL cholesterol. In this review, we focus on the discovery of TM6SF2 and its role in VLDL secretion pathways. Human data suggest TM6SF2 is linked to hepatic steatosis and cardiovascular disease (CVD), hence understanding its metabolic pathways is of high scientific interest. Recent findings Since its discovery, completed research studies in cell, rodent and human models have defined the role of TM6SF2 and its links to human disease. TM6SF2 resides in the endoplasmic reticulum (ER) and the ER-Golgi interface and helps with the lipidation of nascent VLDL, the main carrier of triglycerides from the liver to the periphery. Consistent results from cells and rodents indicated that the secretion of triglycerides is reduced in carriers of the p.E167K variant or when hepatic TM6SF2 is deleted. However, data for secretion of APOB, the main protein of VLDL particles responsible for triglycerides transport, are inconsistent. Summary The identification of genetic variants that are highly associated with human disease presentation should be followed by the validation and investigation into the pathways that regulate disease mechanisms. In this review, we highlight the role of TM6SF2 and its role in processing of liver triglycerides.

show abstract

“…Актуальность изучения неалкогольной жировой болезни печени (non-alcoholic fatty liver disease -NAFLD)/ метаболически-ассоциированной жировой болезни печени (metabolic associated fatty liver disease -MAFLD) или, согласно последнему пересмотру номенклатуры, «ассоциированной с метаболической дисфункцией стеатозной болезни печени (metabolic dysfunction-associated steatotic liver disease -MASLD)» определяется высоким уровнем распространенности и значимостью исходов. Распространенность данной нозологии в общей популяции в мире достигает 33,0% [1][2][3][4][5][6], заболевание выявляется во всех возрастных группах, у лиц с ожирением частота встречаемости составляет 62-93%. В Российской Федерации это заболевание занимает лидирующую позицию в структуре заболеваний внутренних органов, в 2007 г. его распространенность у пациентов амбулаторных лечебно-профи-лактических учреждений составляла 27%, а в 2015 г.…”

Section: Introductionunclassified

“…У 90% пациентов с NAFLD имеется один компонент метаболического синдрома (МС) и более, у 30% -все составляющие МС. Данная нозологическая форма болезни представляется фактором риска развития заболеваний сердечно-сосудистой системы [6][7][8]. Частота NAFLD среди пациентов с сахарным диабетом 2-го типа (СД 2) и ожирением составляет 70-100%.…”

Section: Introductionunclassified

The clinician's view on the advantages and contradictions of the new nomenclature of steatotic liver disease: A review

Pavlov,

Teplyuk,

Lazebnik

et al. 2024

Terapevticheskii arkhiv

View full text Add to dashboard Cite

In September 2023, the European Association for the Study of the Liver (EASL) updated the disease nomenclature for non-alcoholic (metabolically associated) fatty liver disease. The goals of the revision were to increase awareness among health care professionals, civil society and patients about the disease, its course, treatment and outcomes; combating stigma; focusing on the initial etiological factor, including the main (cardiometabolic) risk of disease progression; improved diagnosis based on disease biomarkers; positive impact on the potency to search for new drugs; the ability to provide personalized medical care. The terms “non-alcoholic” and “fatty” were considered stigmatizing, and therefore, it was proposed to use the term steatotic liver disease (SLD) as the name of this nosology. The terms non-alcoholic fatty liver disease (NAFLD) or metabolic associated fatty liver disease (MAFLD) have been replaced by the term metabolic dysfunction-associated steatotic liver disease (MASLD). In the case of being combined with an alcohol factor, a diagnosis in which metabolic dysfunction is combined with alcoholic liver disease is referred to as MetALD. The fundamental principle in the diagnosis of MASLD is the presence of at least one of the cardiometabolic risk factors. Alcohol consumption interacts with cardiometabolic risk factors and increases the risk of SLD decompensation. The term nonalcoholic steatohepatitis (NASH), according to the new nomenclature, has been replaced by the term metabolic dysfunction-associated steatohepatitis (MASH). The adoption of the new nomenclature should help to increase awareness about the disease, its course and outcomes, as well as improve the quality of diagnosis and treatment.

show abstract

Management of cardiovascular risk in patients with metabolic dysfunction-associated steatotic liver disease

Cited by 24 publications

References 87 publications

Dyslipidemia, Cholangitis and Fatty Liver Disease: The Close Underexplored Relationship: A Narrative Review

Dyslipidemia, Cholangitis and Fatty Liver Disease: The Close Underexplored Relationship: A Narrative Review

Basic and translational evidence supporting the role of TM6SF2 in VLDL metabolism

The clinician's view on the advantages and contradictions of the new nomenclature of steatotic liver disease: A review

Contact Info

Product

Resources

About